Figure 2. Summary of efficacy and safety of a ritonavir-boosted protease inhibitor plus
lamivudine or tenofovir disoproxil fumarate (two-drug regimen [2DR]) versus three-drug
regimen (3DR).
This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.
Figure 2. Summary of efficacy and safety of a ritonavir-boosted protease inhibitor plus
lamivudine or tenofovir disoproxil fumarate (two-drug regimen [2DR]) versus three-drug
regimen (3DR).